IMPRINT
Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2023
25th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) November 30- December 2, 2017, Vienna, Austria
/in NewsOn Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink lectured during the session: Breast cancer risk from hormonal treatment.
The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”.
For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer
First patient enrolled in clinical study with the fetal estrogen estetrol (E4) in patients with advanced breast cancer (the ABCE4 study)
/in NewsThe first patient has been enrolled in the Phase I/II clinical trial assessing safety and efficacy of estetrol (E4) in postmenopausal women with advanced ER+ breast cancer. The study is a multi-center, open-label, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of E4 for the treatment of patients with advanced breast cancer. In total 9-18 patients will be enrolled at three centers in Germany.
The main objectives of this study are to evaluate the safety, the effects on estrogen deficiency symptoms and the preliminary anti-tumor activity of E4 in patients with advanced breast cancer.
Contribution of Pantarhei Bioscience to the Congress of the European Society of Gynecology (ESG), 18-21 October, 2017 in Barcelona by an invited lecture of Herjan Coelingh Bennink
/in NewsSymposium on Sexuality / Women’s Sexual Dysfunction
Friday October 20, 2017
Chairpersons: Ali Kubba and Josep Perello
Programme:
Rossella E. Nappi:
Sexual symptoms at menopause: are they all women’s dysfunction?
Johannes Bitzer:
Sexual health care for cancer patients.
Rik HW van Lunsen:
The Amsterdam multifacettel approach of sexual pain disorders aiming at restoring sexual pleasure.
Herjan J.T. Coelingh Bennink:
Improvement of sexual function during pill use by normalising free testosterone levels.
For more information please read the abstract: Abstract ESG Barcelona Oct 2017